We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Biotech Company Introduces Mass Density Genome Analysis for Personalized Medicine

By LabMedica International staff writers
Posted on 09 Nov 2011
A biotech company in the United Kingdom is offering assay development and clinical testing services for personalized medicine using technology with advanced rapid gene sequencing and genotyping capabilities.

NewGene (Newcastle upon Tyne, United Kingdom) is a young company jointly owned by the Newcastle Hospitals NHS (National Health Service) Foundation Trust and Newcastle University. More...
The company has recently introduced a tumor marker-identification service based on the Sequenom analyzer platform.

The Sequenom is a high capacity mass array DNA analyzer that uses MALDI (matrix-assisted laser desorption/ionization) TOF (time of flight) mass spectrometry. This technology is able to distinguish stretches of DNA sequence that differ by one, or a small number of bases. Short oligonucleotides are extended, usually by a single base at the position of the sequence variant. The TOF of the extended oligonucleotide within the vacuum chamber of the Sequenom is an accurate indicator of its mass and from this the genotype is determined. Variant detection can be carried out in multiplex, with up to 30 sites targeted in a single assay.

NewGene is using this platform both qualitatively and quantitatively to determine SNP (single nucleotide polymorphism) variants in mRNA and to detect previously described “common” mutations in specific disease causative genes.

In addition, NewGene is working closely with major pharmaceutical companies on the use of its fast throughput and flexible molecular pathology test platform to develop new clinical assays in response to the introduction of new genomic-based medicines.

Dr. Michael Wright, a director of NewGene, said, “There is clearly significant current interest in the power and effectiveness of targeted therapies and this has resulted in considerable growth in demand for biomarker testing services. Traditionally molecular testing does not have a natural base in NHS pathology laboratories. NewGene’s dedicated service overcomes this problem by harnessing the capabilities of the latest sequencing and genotyping technology alongside specialist clinical molecular genetics and research skills. More importantly we believe that such developments represent a significant step forwards towards comprehensive tumor profiling and more informed cancer therapy, which in turn will lead to better patient outcomes.”

Related Links:
NewGene



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.